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considerably over the last few decades. With a 5-year
overall survival of more than 80%,1 the majority of
childhood cancer patients nowadays will become long-
term survivors. Unfortunately, the improved survival is
accompanied by the occurrence of late adverse effects of
treatment.2,3 The cardiotoxic side effects of certain
cancer treatments such as anthracyclines and chest
directed radiotherapy are well-known and include heart
failure, arrhythmias, coronary artery disease, valvular
abnormalities and pericardial disease.4
Of these cardiotoxic side effects, cancer therapy-
related heart failure in childhood cancer survivors
(CCS) is the most frequently encountered problem:
almost 5% of all CCS develops clinical heart failure within
40 years after childhood cancer diagnosis.5 Moreover,
mortality due to heart failure is six-fold higher in long-
term CCS as compared to the general population and
treatment related cardiac death is the leading cause of
death after malignancies.6,7
Before clinical heart failure, a larger proportion of long-
term CCS have a subclinical decline in left ventricular
(LV) systolic function. The prevalence of subclinical LV
systolic dysfunction varies in the literature, and is about
30% in different follow up periods when defined as a two-
dimensional ejection fraction (EF) b50% or fractional
shortening (FS) b30%.3,8 In a recent study, prevalence of
LV dysfunction was only 5.8% after a median follow up of
23 years but in that study LV systolic dysfunction was
defined with more constraint as a three-dimensional EF
b50%.9 The Dutch surveillance guideline for long-term
CCS defines cancer therapy-related cardiac dysfunction as
a FS b30% or EFb 50%.10
Established treatment related risk factors for heart
failure and subclinical LV systolic dysfunction in CCS
are higher cumulative anthracycline doses (in a non-
linear fashion with no safe dose threshold), higher
cumulative mitoxantrone dose and chest directed
radiotherapy (especially in combination with anthracy-
clines).2,3,11 The type of anthracycline analogue and
anthracycline infusion duration might also play a
role.12-16
Surveillance for subclinical cardiac dysfunction may
prevent further deterioration of LV function by timely
initiating heart failure therapies.17,18
Currently, EF measured by two-dimensional echocardi-
ography is the main parameter used in the surveillance
for cancer therapy-related cardiac dysfunction and for
clinical decision making in CCS.16,19 However, the
usefulness of EF is limited by a large variability of 10%.20
In the general population myocardial strain imaging
emerges as a valuable tool to detect subclinical LV
dysfunction that is superior in predicting heart failure and
all-cause mortality compared to two-dimensional EF.21-23
The prevalence of global longitudinal strain abnormalities
in CCS with a preserved three-dimensional ejectionfraction was 28% in a cohort study in 1820 CCS at a
median of 23 years after cancer diagnosis.9
Another echocardiographic tool next to LV systolic
dysfunction determined by 2D echocardiography is LV
diastolic dysfunction which is encountered in 9–21% of
long-term CCS, with severe dysfunctions mainly after
(additional) chest directed radiotherapy.8,9,24 Also dia-
stolic dysfunction is a predictor of future heart failure in
the general population.25,26
Studies have been performed that identified blood
biomarkers that can detect subclinical cancer-treatment
related cardiac dysfunction.16 However, blood biomarkers
are not yet recommended in the surveillance for cardiac
dysfunction in long-term CCS.10,16 Recently, we reviewed
the literature on blood biomarkers for the diagnosis of LV
dysfunction in long-term CCS and showed that NT-proBNP
and troponins have a limited diagnostic value, which
underlines the need to find more accurate biomarkers.27
The ability of ECG parameters to early detect cancer
therapy-related cardiac dysfunction in CCS remains
unknown.16,28 Several studies in long-term CCS describe
a high incidence and variety of electrocardiographic
abnormalities.29 Major ECG abnormalities were predic-
tive for cardiac and all-cause mortality in a large CCS
cohort but were not compared with echocardiographic
abnormalities.30 In a smaller long-term CCS cohort ECG
abnormalities (mainly conduction disorders, high ampli-
tude R waves and sinus bradycardia) were not predictive
for echocardiographic abnormalities.28 However, only
one of these 340 CCS had evidence of systolic LV
dysfunction with an EFb 50% and strain parameters were
not measured.
There are still gaps in knowledge that needs to be
addressed in order to improve the surveillance for
cardiomyopathy in CCS.16 These gaps include 1) the
use of echocardiographic parameters for early detection
of cardiomyopathy, 2) the accuracy of biomarkers and
ECG parameters to diagnose subclinical cardiac dysfunc-
tion, 3) the cardiotoxicity of non-anthracycline contain-
ing chemotherapy, such as high-dose cyclophosphamide,
ifosfamide and vincristine,3,5,13 4) the role of genetics in
the susceptibility for cardiomyopathy and 5) the com-
bined use of blood biomarkers, ECG and echocardiogra-
phy for the detection of subclinical cardiac dysfunction.
Considering these knowledge gaps, more information
from echocardiography including myocardial strain,
blood biomarkers (including genetics) and ECG measure-
ments for the early detection of cardiac dysfunction in
CCS and their associations with cancer treatment
exposures is needed. In this paper we will describe the
methodological aspects of the Dutch LATER cardiology
study (LATER CARD) project that focusses on subclinical
cardiac dysfunction in CCS who received (potential)
cardiotoxic cancer treatment(s) as detected by echocar-
diographic parameters including myocardial strain, blood
biomarkers and ECG parameters.
Figure 1
Flowchart of potentially eligible patients in the LATER CARD study. Cancer diagnosis dates of CCS in the LATER CARD study were between 1963 and
2001. Patient enrollment in the DCOG-LATER CARD study started in February 2017 and we are planning to include participants until March 2020.
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Funding
The LATER CARD study is supported by grants from the
Dutch Heart Foundation (CVON2015–21) and Kika/
ODAS (grant 171 ‘DCOG LATER program’).
Objectives
The main objectives of the LATER CARD study are to
evaluate 1) the prevalence and associated (treatment
related) risk factors of subclinical cardiac dysfunction in
CCS compared to sibling controls and 2) the diagnostic
value of echocardiography including myocardial strain
and diastolic function parameters, blood biomarkers and
ECG or combinations of them in the detection of cancer
therapy-related cardiac dysfunction.
The LATER CARD study is subdivided into six work
packages (WPs) with different objectives that support the
main objective. WP1 consists of the data collection
management that is required for the other WPs and does
not address a specific research question. In WP2 we will
study the prevalence and treatment related risk factors for
subclinical systolic cardiac dysfunction including strain
and diastolic LV dysfunction identified by echocardiog-
raphy. WP3 concerns the prevalence of blood biomarker
abnormalities and associated treatment related risk
factors. In WP4 the prevalence and associated treatment
related risk factors of abnormal ECG measurements will
be studied. The diagnostic tools studied in WP 2, 3 and 4will then be compared with respect to their diagnostic
value in detecting subclinical cardiac dysfunction (see
“Definitions” below). WP5 will study the gender differ-
ences in the prevalence of subclinical cardiac dysfunc-
tion, abnormal blood biomarker values and ECG
abnormalities. In WP6 the results of all other WPs will
be combined to formulate guideline recommendations
for the cardiac surveillance of long-term CCS.
Study design
The Dutch LATER CARD study, is part of the Dutch
Childhood Cancer Survivors Study LATER 2 study, a cross-
sectional study of a retrospective nationwide cohort of 5-
year CCS (Figures 1 and 2). The LATER study is a
collaboration between 7 pediatric oncology centers in the
Netherlands (Amsterdam University Medical Center (VU
Medical Center and Academical Medical Center), Leiden
University Medical Center, Erasmus Medical Center, Univer-
sity Medical Center Groningen, Radboudumc and University
Medical Center Utrecht/Wilhelmina Children's Hospital/
Princess Máxima Center for Pediatric Oncology) and
includes a close collaboration with experts for specific
health problems. The study protocol was approved by the
medical ethic boards of all participating centers.
Study population
Informed consent is being obtained from all partici-
pants before study inclusion. The study population is
Figure 2
Study design of the LATER CARD study. The LATER CARD study is sub-divided in workpackages (WPs). WP1 consists of the data collection that is
needed for the other WPs. The results of WP 2,3,4 and 5 will be used to improve the long-term follow-up guideline (WP6).
92 Leerink et al
American Heart Journal
Month Yearobtained from the Dutch LATER nationwide cohort (n =
6165), including all 5-year CCS diagnosed before the age
of 18 years, between 1/1/1963 and 12/31/2001 with a
malignancy according to the third edition of the
International Classification of Childhood Cancer.31 We
only include CCS who were living in the Netherlands at
the time of childhood cancer diagnosis and who were
treated in one of the Dutch pediatric oncology centers.
In the LATER CARD study we will include CCS from the
LATER cohort who were treated with (potentially)
cardiotoxic cancer treatments. The LATER CARD study
will include four risk groups; risk group 1 (nomaximum
number): CCS who received anthracyclines, mitoxan-
trone, or chest directed radiotherapy; risk group 2 (max
n = 100): cyclophosphamide only (no anthracyclines,
mitoxantrone, or chest directed radiotherapy, ifosfamide
or vincristine); risk group 3 (max n = 100): ifosfamide
only (no anthracyclines, mitoxantrone, or chest directed
radiotherapy, cyclophosphamide or vincristine); risk
group 4 (max n = 100): vincristine only (no anthracy-clines, mitoxantrone, or chest directed radiotherapy,
ifosfamide or cyclophosphamide).
As a comparison group 500 healthy siblings recruited
from the participants will be included (Figure 1). We
chose for siblings as the comparison group because they
are of approximately the same age and share a partially
common background risk for cardiac disease based on
genetic make-up and early life influences.
Study timeline
Patient enrollment in the LATER CARD study started in
February 2017 and we are planning to include participants
until 2020.We aim to finish all the analyses in January 2022.
The specific timeline per WP is displayed in Figure 3.
Definitions
LV systolic dysfunctionwill bedefined as a biplane EFb52%
for males and a biplane EF b54% for females, in accordance
with the European Association of Cardiovascular Imaging
recommendations.32 Specific subgroups of LV dysfunction
Figure 3
Timeline of the LATER CARD study and the different work packages (WP).
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40–53% for females) and reduced EF (EF b40%).
LV diastolic dysfunction will be defined as grade N I
diastolic dysfunction according to the European Associ-
ation of Cardiovascular Imaging recommendations.33
Abnormal myocardial strain values will be defined
based on age, sex and vendor specific normal values and
the values obtained in the sibling controls.34
Data collection
The LATER CARD project is one of the 15 projects in
the LATER study, each investigating different organ
systems/topics (e.g. pulmonary, bone, cardiac, psycho-
social, psychosexual). All study participants of the LATER
CARD study will be invited once to the outpatient clinic
in one of the pediatric oncology centers. A research
physician will collect the following data for the LATER
CARD study: (1) Medical history including family history
of cardiovascular diseases, presence of hypertension,
diabetes, hypercholesterolemia and life style factors such
as alcohol use and smoking. (2) A comprehensive medical
history including questions regarding dyspnea, chest
pain, palpitations, dizziness, fainting episodes and pe-
ripheral edema. (3) Diagnostic tests: height and weight,
blood pressure, echocardiographic measurements includ-
ing measurements from the previous echocardiogram (if
available), blood for biomarker sampling and a resting
ECG. All data will be anonymized and stored in a central
database.
Echocardiography. A standardized echocardiogram,
will be performed in all CCS and sibling controls included
in the LATER CARD study in the participating centers.
Standard measurements (including LV dimensions, LV
mass, FS, biplane EF, right ventricular dimensions and
function, systolic pulmonary artery pressure, valveabnormalities, and diastolic function measurements)
will be performed by experienced sonographers. In one
of the participating centers 3-dimensional EFs will be
measured. Additional echocardiographic views are ob-
tained for strain analysis in the corelab. All measurements
will be anonymized and saved on disc (DICOM format).
The analyses will centrally be interpreted by the
echocardiography corelab in the Radboudumc in Nijme-
gen, the Netherlands. The standard measurements will be
reviewed and corrected by the corelab and additional
measurements will be performed (including radial,
circumferential and longitudinal systolic strain and strain
rate, biplane EF, left atrial volume index and diastolic
parameters including tissue Doppler imaging).
Blood sampling. In all CCS and siblings included in
the LATER CARD study, venous blood (divided in plasma
and cell portions) will be collected and stored at −80
degrees Celsius in the LATER biobank in Utrecht. Blood
sample storage will be available for future biomarker
evaluation including the evaluation of genetic suscepti-
bility for cardiac dysfunction.
A panel of 184 protein biomarkers from different
biological processes will be evaluated in a targeted
proteomics study in a nested case–control format within
the LATER CARD study cohort. The 184 markers are part
of the Cardiovascular panel III and the Organ Damage
panel from Olink Proteomics.
The biomarkers, their interactions and their corre-
sponding biological processes are listed in Supplementa-
ry Table 1 and visualized in Supplementary Figure 1.
Biomarker interactions and biological processes were
obtained with STRING, a database which combines data
on protein interactions and biological process classifica-
tions from different curated databases (GO, KEGG,
Reactome).35 The 184 biomarkers are mainly implicated
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load, inflammation, neurohormonal activation, oxidative
stress, extracellular turnover/remodeling, platelet activa-
tion/thrombosis, endothelial dysfunction and lipid
metabolism.36
N-terminal prohormone of brain natriuretic peptide
(NT-proBNP) and biomarkers identified in the case–
control study will be evaluated in the entire LATER CARD
cohort for their diagnostic value (sensitivity, specificity,
negative predictive value and positive predictive value) in
detecting (subclinical) LV systolic dysfunction, abnormal
myocardial strain and LV diastolic dysfunction on
echocardiography.
Genetic analysis will include a genomewide association
study to identify susceptibility loci for cancer-therapy
related cardiac dysfunction. In addition, we will evaluate
the prevalence of genetic variants that are associated with
dilated cardiomyopathy in CCS with cancer-therapy
related cardiac dysfunction and their contribution in the
risk-stratification of CCS.
ECG. In all CCS included in the LATER CARD study
and sibling controls, a 12-lead resting ECG will be
performed. ECGs will be stored centrally and will be
analyzed by the corelab according to the Minnesota
criteria.37
Statistical analysis
Power analyses. The power calculations are per-
formed with a power set at 80% and alpha set at 0.05. To
detect a clinical significant difference in proportion of
subjects with subclinical LV systolic dysfunction (assum-
ing a proportion of 10% in CCS and 1.5% in the sibling
controls) we need n = 128 in each group.
We assume that 13% of the CCS and 2.5% of the sibling
controls will have abnormal NT-proBNP values, adjusted
for age and sex.38,39 Therefore, to detect a significant
difference in proportion of abnormal NT-proBNP values
between the CCS and the sibling controls we need n =
108 in each group.
To detect a clinically significant difference in propor-
tion of major ECG abnormalities of 10% (estimated
proportion in the sibling controls 2.8%40) between the
CCS and the sibling controls we need n = 112 in each
group. However, because we aim to perform subgroup
analyses according to risk factors (gender, cancer
treatment) more CCS and sibling controls will be
included.
Prevalence analyses. The prevalence of LV systolic
dysfunction (defined as a biplane EF b52% for males and
b54% for females32), LV diastolic dysfunction (grades
according to the European Association of Cardiovascular
Imaging33) and abnormal myocardial strain (age, sex and
vendor based normal values34) will be reported and
compared between the different risk groups and with the
sibling controls with theχ2 test. Likewise, the prevalence
of abnormal candidate blood biomarkers and major andminor ECG abnormalities (according to the Minnesota
criteria37) will be reported.
Risk factor analyses. Risk factor analyses for LV
systolic dysfunction, LV diastolic dysfunction, myocardial
strain abnormalities, abnormal blood biomarkers findings
and abnormal ECG measurements will be evaluated using
separate multivariable logistic regression models includ-
ing cancer treatment(s), follow-up time, sex, age at
diagnosis, lifestyle factors (including smoking, alcohol
consumption) and comorbidities (including hyperten-
sion, overweight, diabetes, hypercholesterolemia). The
association between cancer treatment exposures and
echocardiographic measurements (including EF, strain
and diastolic function), blood biomarker values and ECG
measurements will be evaluated with multivariable linear
regression models.
Diagnostic accuracy analyses. The association
between echocardiographic indices, blood biomarker
values and ECG parameters will be tested in linear
regression models. The diagnostic value of blood
biomarkers and ECG parameters to detect LV systolic
dysfunction, LV diastolic dysfunction or strain abnormal-
ities will be evaluated with cut-off points derived from
receiver operating characteristic curves. Optimal cut-off
points for confirming or excluding the presence of LV
systolic dysfunction, LV diastolic dysfunction or strain
abnormalities will be reported with the sensitivity,
specificity, positive predictive value and negative predic-
tive value.”
Subgroup analyses. Subgroup analyses will be
performed in CCS without a (previous) diagnosis of
congestive heart failure (as defined by the European
Society of Cardiology heart failure guideline).19
To detect early markers for subclinical cardiac dysfunc-
tion subgroup analyses will be performed in asymptom-
atic CCS with a normal LV function at the previous
echocardiogram (within 5 years, if available) and without
symptoms of heart failure.
Additional subgroup analyses will be performed for
males and females to evaluate gender differences in
prevalence and risk factors for cardiac dysfunction.
Non-normally distributed variables will be log-
transformed or tested for with the use of non-parametric
tests. Two sided p-values b0.05 will be considered as
statistically significant.
Preliminary results
Study population
Table I presents the characteristics of all eligible CCS
and sibling controls for the LATER CARD study who were
alive on January 1, 2017. The eligible study cohort
includes 3608 CCS and 1066 siblings, the majority of CCS
had a primary diagnosis of leukemia, lymphoma, renal
tumors, bone or soft tissue sarcomas. There are 2566
eligible CCS in risk group 1, 48 eligible CCS in risk group
Table I. Patient, cancer and treatment characteristics of eligible 5-year survivors for the DCOG-LATER CARD cohort and sibling controls.⁎
Characteristics
Potential study population
(n = 4674)
Childhood cancer survivors Sibling controls
n 3608 1066
Sex
Female 1530 (42.4%) 452 (42.4%)
Male 2078 (57.6%) 614 (57.6%)
Primary childhood cancer (ICCC)
Leukemias, myeloproliferative diseases, and myelodysplastic diseases 1641 (45.5%) -
Lymphomas and reticulo-endothelial neoplasms 783 (21.7%) -
CNS and miscellaneous intracranial and intraspinal neoplasms 150 (4.2%) -
Neuroblastoma and other peripheral nervous cell tumors 85 (2.4%) -
Retinoblastoma 1 (0.0%) -
Renal tumors 430 (11.9%) -
Hepatic tumors 36 (1.0%) -
Bone tumors 226 (6.3%) -
Soft tissue and other extraosseous sarcomas 185 (5.1%) -
Germ cell tumors, trophoblastic tumors, and neoplasms of gonads 61 (1.7%) -
Other malignant epithelial neoplasms and malignant melanomas 8 (0.2%) -
Other and unspecified malignant neoplasms 2 (0.0%) -
Age at cancer diagnosis (year)
0–4 1663 (46.1%) -
5–9 989 (27.4%) -
10–14 749 (20.8%) -
15–17 207 (5.7%) -
Cancer treatment period
1963–1979 442 (12.3%) -
1980–1989 1149 (31.8%) -
1990–2001 2017 (55.9%) -
Overall treatment modality
Risk group 1: Anthracyclines/mitoxantrone and/ or chest RT 2566 (71.1%) -
Risk group 2: Cyclofosfamide only 48 (1.3%) -
Risk group 3: Ifosfamide only 33 (0.9%) -
Risk group 4: Vincristine only 961 (26.6%) -
Chest RT = radiation therapy involving the heart region.
⁎ Percentage of the total DCOG-LATER CARD cohort including sibling controls
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risk group 4 (Figure 1).
Inclusion
We expect to include 1900 of the 3608 CCS and 500 of
the 1066 siblings (total study population = 2400) in a
consecutive order. Currently (May 2019), we have
collected data of 1283 CCS and 189 siblings.
Expected results
With the LATER CARD study we will report the
prevalence and relative risk of subclinical cardiac
dysfunction in CCS compared to sibling controls based
on echocardiographic imaging (including abnormal
myocardial strain and LV diastolic dysfunction parame-
ters), blood biomarkers and ECG parameters and their
associations with treatment and gender related risk
factors.
Furthermore, we will determine the value of myocar-
dial strain, blood biomarkers and ECG parameters in thediagnosis of LV dysfunction and their prognostic useful-
ness in the surveillance of long-term CCS at risk for heart
failure (from subgroup analyses of patients with a prior
normal echocardiogram).
In addition, we expect to provide evidence on the
cardiotoxicity of cyclophosphamide, ifosfamide and
vincristine. However, given the low number of CCS
in the cyclophosphamide only and ifosfamide only group
(48 and 33), collaboration with other childhood
cancer survivors cohorts is likely to be necessary before
definite conclusions can be drawn on the cardiotoxicity
of these agents.
Hereby the LATER CARD study will form the basis of an
improved surveillance guideline in long-term CCS.Discussion
In the LATER CARD study, we will investigate the single
and joint contributions of diagnostic tools to detect
cancer therapy-related cardiac dysfunction in a large long-
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therapies. The diagnostic tools (myocardial strain, dia-
stolic function parameters including tissue Doppler
measurements, blood biomarkers and ECG) that we will
study are scarcely investigated in large long-term CCS
cohorts9,16,27,28,30 and were not previously studied in
relationship with each other or compared with
sibling controls.
Two-dimensional EF, measured with echocardiography,
is themost frequently used parameter in the surveillance of
long-term CCS for cancer therapy-related cardiac dysfunc-
tion but is limited by its reproducibility, load dependency
and inability to detect subtle changes in EF.21,41 From
studies in adult oncology patients, we know that early
detection of subclinical cardiac dysfunction is necessary to
prevent cardiac deterioration, by initiating treatment with
heart failure medication.18 Adopting this view, sensitive
markers are needed that are able to detect early signs of
cardiac deterioration before heart failure symptoms occur.
Although, evidence of the diagnostic tools (EF,
longitudinal strain, diastolic function, NT-proBNP and
high sensitive troponins) on future development of heart
failure in long-term CCS is lacking, they are established
predictors for heart failure in the general popula-
tion.23,26,42,43 Therefore, by extrapolating these findings
to CCS we expect that the diagnostic tools evaluated in
the LATER CARD study can identify CCS at higher risk for
development of heart failure, and thus bring benefit from
more frequent surveillance and/or early treatment
initiation. Importantly, the results may also identify CCS
at low risk for heart failure in whom we can decrease the
surveillance frequency.
In addition, with sub-group analyses of patients with a
normal prior echocardiogram we may infer the role of
these diagnostic tools in the natural history of cancer
therapy-related cardiac dysfunction.
A limitation of the LATER CARD study is that it is of cross-
sectional nature and therefore may not be able to validate
the findings in predicting future cardiac dysfunction in those
patients that do not have cardiac dysfunction or only minor
signs of them. The study is therefore mainly able to discern
those patients with early or progressed LV dysfunction from
those with no dysfunction and therefore mainly to diagnose
or exclude the presence of clinically important LV
dysfunction with either of the diagnostic tools. As the
study is conducted in a large cohort of CCS who previously
received regular surveillance by echocardiography accord-
ing to prevailing guidelines,10 we may be able to identify
which markers are markers of progression for cardiac
dysfunction and provide additional evidence for risk
assessments. Still, future follow up studies of our cohort
will be needed to confirm the value of the described
diagnostic tools as early markers for clinical heart failure in
long-termCCS. Furthermore, the number of patients eligible
for the cyclophosphamide only and ifosfamide only group
was limited, as treatment with these agents alone is rare.Future collaborations with other long-term childhood
cancer survivor cohort may be necessary to draw definite
conclusions on the cardiotoxicity of these agents.
Eventually, the results of the LATER CARD study will
provide the evidence to improve long-term follow up
guidelines, which we aim to complete at the end of this
project. Furthermore this project will form the basis for
future prospective follow-up studies that will increase the
knowledge on the predictive value of the described tests.
This project will be carried out by a multidisciplinary
team of caregivers and researchers in the field of cancer
therapy-related cardiac dysfunction in long-term CCS.
This team will enable the implementation of the
improved guideline recommendations in a broad field
of health professionals involved in the care for CCS.
Conclusion
The Dutch LATER CARD study will investigate diagnos-
tic tools to detect subclinical cardiac dysfunction in long-
term CCS treated with potential cardiotoxic cancer
therapies. This will be an important study to investigate
the relationship between clinical data, echocardiograph-
ic, blood biomarker and ECG measurements to detect
cardiac dysfunction in a large nationwide cohort of CCS.
The results will form the basis of an improved long-term
follow up guideline to ultimately prevent heart failure in
this population.
Supplementary data to this article can be found online
at https://doi.org/10.1016/j.ahj.2019.10.010.
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